Chimerix to Announce Third Quarter 2018 Financial Results on November 8, 2018
DURHAM, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Thursday, November 8, 2018 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2018, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 4646308. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, . An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, .
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
or
Will O’Connor
Stern Investor Relations
(212) 362-1200
Media:
Laurie Masonson
W2O Group
(917) 459-6164
